Date: 2017-04-03
Type of information: Company acquisition
Acquired company: assets and relevant business related to the CELLSEARCH® Circulating Tumor Cell System from Janssen Diagnostics (USA - PA)
Acquiring company: Menarini-Silicon Biosystems, a Menarini group company (Italy)
Amount: undisclosed
Terms:
- • On April 3, 2017, Menarini-Silicon Biosystems announced it completed the agreement to purchase all the assets and relevant business related to the CELLSEARCH® Circulating Tumor Cell System from Janssen Diagnostics. Under the agreement, Menarini-Silicon Biosystems will assume operations of the seller’s CLIA-certified laboratory in Huntingdon Valley. Menarini Diagnostics, a Menarini Group company, will operate the business in Europe, while Menarini Silicon Biosystems. will lead the business in the U.S. and the rest of the world. Not all operations will be transferred simultaneously, the present closing relates to US and Europe while the closing for the rest of the world will follow at a later stage. Financial details were not disclosed.
- • On December 20, 2016, Menarini-Silicon Biosystems today announced they have signed an agreement to purchase all the assets and relevant business related to the CELLSEARCH® Circulating Tumor Cell (CTC) system from Janssen Diagnostics. Under terms of the agreement, when the closing will occur, Menarini-Silicon Biosystems will seek to retain many of the Janssen Diagnostics employees in roles dedicated to CTCs, and assume operation of Janssen Diagnostics’ CLIA-certified laboratory in Huntingdon Valley, Pennsylvania. The two companies will work closely to transition the business across the many global markets where CELLSEARCH® is available.
Details:
- This acquisition is marking Menarini-Silicon Biosystems’ first entry into the U.S. diagnostics market. The operation includes the CELLSEARCH® Circulating Tumor Cell Test. This test is the first and only clinically validated blood test cleared by the FDA for detecting and enumerating circulating tumor cells (CTCs) to help manage patients with metastatic breast, prostate, and colorectal cancers. The test is also approved by the China Food and Drug Administration for use in monitoring metastatic breast cancer patients.
- The acquisition is part of Menarini-Silicon Biosystems’ objective to develop companion diagnostics that allow selecting patients more likely to respond to targeted drug treatments, and that accelerate the validation of personalized therapies. The CELLSEARCH® product line, which includes the CELLTRACKS® AUTOPREP SYSTEM, the CELLSEARCH® Analyzer II and the CELLSEARCH® CTC Kit, will join Menarini-Silicon Biosystems’ growing family of advanced diagnostics led by its DEPArray™ NxT System (for research use only). The DEPArray NxT digital cell-sorting and isolation system, complemented by the Ampli1 kits, enable rare-cell isolation and genetic analyses, and are used in clinical research to achieve molecular characterization with single-cell precision. With both DEPArray™ and CELLSEARCH® in its portfolio, Menarini-Silicon Biosystems will be able to provide CTC detection on an FDA-cleared platform, and give oncologists and researchers access to unparalleled molecular characterization capabilities. Together, the two technologies provide opportunity to advance next-generation, personalized medicine strategies.
Related: Cancer - Oncology - Diagnostic
Is general: Yes
